VEGF-C Agonists Inhibit UVB-Induced Skin Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
UVB irradiation leads to enlargement and impairment of lymphatic vessels, causing hyperpermeability and contributing to skin damage, with enhanced VEGF-A expression but not VEGF-C or VEGF-D in the epidermis.
Innovation Solution
Methods to reduce UVB-induced skin damage by decreasing VEGF-A activity or levels in the skin, increasing lymphangiogenic factors like VEGF-C or VEGF-D, and using VEGF/VEGFR modulators such as antagonists or agonists to regulate lymphatic vessel function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Shape
If VEGF-A expression is enhanced in UVB-irradiated epidermis, then lymphatic vessel enlargement occurs, but lymphatic vessel function is impaired and hyperpermeability increases
Solution Approach 1:
The patent extracts and targets VEGF-A specifically as the problematic factor causing lymphatic vessel enlargement and hyperpermeability. By identifying VEGF-A as the unique mediator (not VEGF-C or VEGF-D) responsible for these adverse effects, the invention enables selective inhibition of VEGF-A signaling to restore lymphatic vessel function while preserving normal lymphangiogenesis.
Solution Approach 2:
The patent changes the functional state of lymphatic vessels by modulating VEGF-A signaling parameters. Through blockade of VEGF-A signaling, the patent reverses the pathological enlargement and hyperpermeability, restoring vessels to a functional state. This parameter change approach transforms the vessel morphology and function from impaired to healthy.
2Reliability
If VEGF-A signaling is blocked, then lymphatic vessel abnormalities are prevented, but the mechanism to restore lymphatic function remains to be established
Solution Approach 1:
The patent introduces VEGF-A as the key intermediary mediator between UVB irradiation and lymphatic vessel damage. By blocking this specific mediator, the patent prevents the adverse effects without needing to directly manipulate the complex lymphatic vessel structure itself, simplifying the therapeutic mechanism.
Solution Approach 2:
The patent applies preliminary action by blocking VEGF-A signaling before UVB-induced lymphatic vessel abnormalities fully develop. This preventive approach stops the pathological process at its source, avoiding the need for complex corrective measures after damage occurs.
3Productivity
If lymphatic vessel enlargement occurs after UVB irradiation, then drainage capacity increases, but permeability increases causing edema
Solution Approach 1:
The patent applies local quality by targeting VEGF-A specifically in the epidermis and upper dermis where UVB irradiation occurs. This localized inhibition prevents VEGF-A-mediated lymphatic vessel abnormalities in the irradiated area while leaving other tissues unaffected, addressing the harmful permeability changes without compromising overall drainage function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Prevents lymphatic vessel abnormalities and photo-damage by reducing VEGF-A activity, promoting lymphatic function, and ameliorating UVB-induced skin damage by targeting VEGF-A signaling pathways.
Implementation Method 1
VEGF-A mediates impairment of lymphatic vessel function and thereby contributes to the adverse effects of UVB irradiation on the skin
Implementation Method 2
The expression levels of vascular endothelial growth factor (VEGF)-A, but not of the known lymphangiogenesis factors VEGF-C or -D were enhanced in UVB-irradiated epidermis
Implementation Method 3
One known function of lymphatic vessels is the drainage of tissue fluid from normal and inflamed tissues
Data Source
AI summary
This application features methods of inhibiting ultraviolet B-induced skin damage in a subject. The methods include administering a VEGF-C agonist to the subject.